Suda : 1646021.pdf

ACN 090 987 250

It is anticipated an announcement updating the market will be made on or before Monday, 27 February 2017.

For the purposes of ASX Listing Rule 17.2, and in support of its request, the Company advises that:

1. The extension of the suspension is requested pending an announcement by the Company in relation to this matter with the estate of HC Berlin Pharma;

2. It is anticipated that an announcement updating the market will be made on or before Monday, 27 February 2017; and

3. it is not aware of any reason why the suspension should not be granted.

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes Zolpimist™, a first-in-class oral spray of zolpidem for insomnia. Zolpimist™ is marketed in the USA and SUDA has rights to the product outside of North America. SUDA's most advanced development-stage product, ArTiMist®, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist® was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au